blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2528585

EP2528585 - PHARMACEUTICAL COMPOSITIONS COMPRISING TIOTROPIUM, FORMOTEROL AND BUDESONIDE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.07.2020
Database last updated on 14.11.2024
FormerThe patent has been granted
Status updated on  21.06.2019
FormerGrant of patent is intended
Status updated on  10.04.2019
FormerExamination is in progress
Status updated on  07.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Bilgic, Mahmut
Yildiz Teknik Universitesi
Davutpasa Kampusu
Teknoloji Gelistirme Bolgesi
D Blok
34220 Esenler-Istanbul / TR
[2013/04]
Former [2012/49]For all designated states
Bilgic, Mahmut
Tozkoparan Mah. General Ali Riza Gurcan Cad.
Merter IsMerkezi Bagimsiz Bolum No:2/13 Merter
Istanbul 34173 / TR
Inventor(s)01 / see applicant
...
 [2012/49]
Representative(s)(deleted)
[2012/49]
Application number, filing date11706963.328.01.2011
[2019/30]
WO2011TR00019
Priority number, dateTR2010000068029.01.2010         Original published format: TR 201000680
[2012/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011093817
Date:04.08.2011
Language:EN
[2011/31]
Type: A1 Application with search report 
No.:EP2528585
Date:05.12.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 04.08.2011 takes the place of the publication of the European patent application.
[2012/49]
Type: B1 Patent specification 
No.:EP2528585
Date:24.07.2019
Language:EN
[2019/30]
Search report(s)International search report - published on:EP04.08.2011
ClassificationIPC:A61K9/00, A61K31/381, A61K31/58, A61K31/167, A61K45/06, A61K31/46, A61K31/439, A61P11/08
[2019/16]
CPC:
A61K9/0075 (EP); A61K31/167 (EP); A61K31/381 (EP);
A61K31/439 (EP); A61K31/58 (EP); A61K45/06 (EP);
A61P11/08 (EP) (-)
C-Set:
A61K31/167, A61K2300/00 (EP);
A61K31/381, A61K2300/00 (EP);
A61K31/439, A61K2300/00 (EP);
A61K31/58, A61K2300/00 (EP)
Former IPC [2019/13]A61K9/00, A61K31/381, A61K31/58, A61K31/167, A61K45/06, A61K31/46, A61K31/439
Former IPC [2012/49]A61K9/00, A61K31/381, A61K31/58, A61K31/167, A61K45/06, A61K31/46
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/49]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT TIOTROPIUM, FORMOTEROL UND BUDESONID[2012/49]
English:PHARMACEUTICAL COMPOSITIONS COMPRISING TIOTROPIUM, FORMOTEROL AND BUDESONIDE[2012/49]
French:COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU TIOTROPIUM, DU FORMOTÉROL ET DU BUDÉSONIDE[2012/49]
Entry into regional phase13.08.2012National basic fee paid 
13.08.2012Designation fee(s) paid 
13.08.2012Examination fee paid 
Examination procedure27.08.2012Examination requested  [2012/49]
26.03.2013Amendment by applicant (claims and/or description)
23.08.2013Despatch of a communication from the examining division (Time limit: M06)
13.02.2014Reply to a communication from the examining division
08.08.2016Despatch of a communication from the examining division (Time limit: M06)
17.03.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
26.05.2017Reply to a communication from the examining division
18.04.2018Despatch of a communication from the examining division (Time limit: M04)
17.08.2018Reply to a communication from the examining division
11.04.2019Communication of intention to grant the patent
13.06.2019Receipt of the translation of the claim(s)
14.06.2019Fee for grant paid
14.06.2019Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.08.2013
Opposition(s)03.06.2020No opposition filed within time limit [2020/32]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
24.05.2017Request for further processing filed
24.05.2017Full payment received (date of receipt of payment)
Request granted
13.06.2017Decision despatched
Fees paidRenewal fee
12.11.2012Renewal fee patent year 03
24.01.2014Renewal fee patent year 04
06.01.2015Renewal fee patent year 05
05.01.2016Renewal fee patent year 06
25.01.2017Renewal fee patent year 07
26.01.2018Renewal fee patent year 08
31.01.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.01.2011
AL24.07.2019
AT24.07.2019
CY24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
MK24.07.2019
MT24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
GB28.01.2020
IE28.01.2020
LU28.01.2020
BE31.01.2020
CH31.01.2020
FR31.01.2020
LI31.01.2020
[2022/32]
Former [2022/27]HU28.01.2011
AL24.07.2019
AT24.07.2019
CY24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
MT24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
GB28.01.2020
IE28.01.2020
LU28.01.2020
BE31.01.2020
CH31.01.2020
FR31.01.2020
LI31.01.2020
Former [2021/08]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
GB28.01.2020
IE28.01.2020
LU28.01.2020
BE31.01.2020
CH31.01.2020
FR31.01.2020
LI31.01.2020
Former [2020/51]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
GB28.01.2020
LU28.01.2020
BE31.01.2020
CH31.01.2020
FR31.01.2020
LI31.01.2020
Former [2020/48]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
GB28.01.2020
LU28.01.2020
FR31.01.2020
Former [2020/46]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
LU28.01.2020
Former [2020/39]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
MC24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/37]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SI24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/36]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/27]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SK24.07.2019
SM24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
PT25.11.2019
IS24.02.2020
Former [2020/25]AL24.07.2019
AT24.07.2019
CZ24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
SK24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
PT25.11.2019
IS24.02.2020
Former [2020/24]AL24.07.2019
AT24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
PT25.11.2019
IS24.02.2020
Former [2020/23]AL24.07.2019
AT24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
IT24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
PL24.07.2019
RO24.07.2019
RS24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/22]AL24.07.2019
AT24.07.2019
DK24.07.2019
EE24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
RS24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/15]AL24.07.2019
AT24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
RS24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/12]AT24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
RS24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
IS24.11.2019
PT25.11.2019
Former [2020/11]AT24.07.2019
ES24.07.2019
FI24.07.2019
HR24.07.2019
LT24.07.2019
LV24.07.2019
NL24.07.2019
RS24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
GR25.10.2019
PT25.11.2019
Former [2020/10]AT24.07.2019
FI24.07.2019
LT24.07.2019
NL24.07.2019
SE24.07.2019
BG24.10.2019
NO24.10.2019
PT25.11.2019
Former [2020/09]FI24.07.2019
LT24.07.2019
NL24.07.2019
NO24.10.2019
Former [2020/08]LT24.07.2019
NL24.07.2019
NO24.10.2019
Former [2020/07]NL24.07.2019
Cited inInternational search[Y]WO0249616  (ASTRAZENECA AB [SE], et al) [Y] 1-28 * page 3, line 33 - page 4, line 2 * * page 4, line 24 - page 5, line 4 * * page 5, lines 21-24 *;
 [A]WO03000241  (BOEHRINGER INGELHEIM PHARMA [DE], et al) [A] 1-28* the whole document *;
 [IY]WO2004019985  (CIPLA LTD [IN], et al) [I] 1-28 * page 3, paragraph 1 - page 6, paragraph last * * examples 31-33; claims 1-33 * [Y] 1-28;
 [I]WO2005053648  (MICRODRUG AG [CH], et al) [I] 1-28 * page 1, lines 3-6 * * page 9, lines 18-34 * * page 17, line 11 - page 19, line 5 * * page 20, lines 1-13; figures 1-5; claims 1-19 *;
 [IY]WO2005053646  (MICRODRUG AG [CH], et al) [I] 1-28 * page 1, paragraph 1 * * page 10, line 29 - page 11, line 9 * * page 12, line 10 - page 14, line 29 * * page 16, lines 1-15 * * page 16, line 25 - page 28, line 2 * * figures 1-5; claims 1-44 * [Y] 1-28;
 [IY]WO2008102128  (CIPLA LTD [IN], et al) [I] 1-28 * page 1, lines 1-9 * * page 4, lines 11-32 * * page 5, lines 28-30 * * example 46 * * claims 1-42 * [Y] 1-28;
 [A]US2009311314  (HARTIG MAREKE [DE], et al) [A] 1-28 * the whole document *;
 [Y]  - WELTE TOBIAS ET AL, "Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, (20090101), vol. 180, no. 8, ISSN 1073-449X, pages 741 - 750, XP009147846 [Y] 1-28 * abstract * * figures 3-6; tables 2-4 *

DOI:   http://dx.doi.org/10.1164/rccm.200904-0492OC
 [Y]  - WELTE ET AL, "Optimising treatment for COPD - new strategies for combination therapy", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, MEDICON INTERNATIONAL, ESHER, GB, (20090101), vol. 63, no. 8, ISSN 1368-5031, pages 1136 - 1149, XP009147844 [Y] 1-28 * figure 5; table 3 * * page 1144, column r, paragraph 2 - page 1147, column l, paragraph 2 *

DOI:   http://dx.doi.org/10.1111/j.1742-1241.2009.02139.x
Examination   - XIAN MING ZENG ET AL, "EFFECTS OF PARTICLE SIZE AND ADDING SEQUENCE OF FINE LACTOSE ON THE DEPOSITION OF SALBUTAMOL SULPHATE FROM A DRY POWDER FORMULATION", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, (19990101), vol. 182, no. 2, doi:10.1016/S0378-5173(99)00021-6, ISSN 0378-5173, pages 133 - 144, XP001030465

DOI:   http://dx.doi.org/10.1016/S0378-5173(99)00021-6
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.